Pharma · · 8 min read
How to evaluate AI for clinical study reports
Acumen Editorial · Updated November 22, 2026
The clinical study report is where a trial becomes evidence. It is also where AI is making some of its fastest gains in pharma.
The numbers are now public. McKinsey reports that a platform it built with Merck cut first-draft CSR writing time from 180 hours to 80 and reduced errors by 50 percent. eMarketer reports turnaround fell from two to three weeks to three to four days. On September 3, ICON said its writers see drafting timelines drop by roughly 30 percent when AI takes over manual drafting.
Speed is no longer the question. The question is how you prove a draft is right before it goes into a submission. As Peer AI's CEO Anita Modi told Pharmaceutical Technology, "human oversight and expert judgement are critical." Here is how we would test a CSR drafting tool.
What does AI actually do in CSR writing?
Most tools draft from the study's own source documents. ICON describes retrieval-augmented generation that pulls from the protocol, the statistical analysis plan (SAP) and the tables, listings and figures (TLFs) to produce a grounded first draft, using sponsor templates and curated prompt libraries.
In practice that covers:
- Results text. Turning TLFs into narrative for efficacy and safety sections.
- Methods. Restating design, populations and endpoints from the protocol and SAP.
- Synopsis and summaries. Condensing the body into the opening sections.
- Safety narratives. Drafting patient-level narratives from listings.
- Consistency work. Terminology, cross-references and formatting.
The writer's job shifts from typing to checking. That makes the check the product.
Why is a CSR harder to test than other AI writing?
Because a fluent error is worse than an obvious one.
Small errors spread. ICON warns that fully automated CSR generation can misinterpret data or reach conclusions that look credible but are wrong, and that small misunderstandings in data-heavy sections can carry into larger errors across the document. A wrong denominator in one table can change the synopsis, the discussion and the conclusions.
Interpretation is a judgment call. A draft can match every number and still overstate an effect, bury a safety signal or describe a post hoc analysis as prespecified. Catching that takes a statistician and a clinician, not a spellchecker.
The window is short. ICON notes writing teams are often notified about two months before database lock. McKinsey reports some companies now file eight to 12 weeks after lock. Faster drafts only help if review keeps up.
Regulators expect a risk-based approach. The FDA and EMA Guiding Principles of Good AI Practice in Drug Development, released January 14, 2026, call for risk-based performance assessment, data governance, data quality and life cycle management. A CSR feeds a marketing application, so it sits at the high-stakes end of that scale.
What should you measure?
Score every drafted section on the same rubric. These are the dimensions we use as a starting point.
| Dimension | What good looks like | Who should score it | Typical failure |
|---|---|---|---|
| Numeric fidelity | Every number, percentage and p-value matches the TLFs | Biostatistician or QC reviewer | Value pulled from the wrong population or table |
| Traceability | Each claim links to a protocol, SAP or TLF source | Medical writer | Statement with no source, or the wrong source |
| Protocol and SAP alignment | Endpoints, populations and analyses described as planned | Biostatistician | Exploratory analysis written up as primary |
| Interpretation | Conclusions match the strength of the evidence | Clinician in the therapy area | Overstated efficacy or understated uncertainty |
| Safety completeness | Every relevant adverse event and signal is reported with context | Safety physician | Signal present in listings but missing from text |
| Internal consistency | Synopsis, body and conclusions agree | Medical writer | Synopsis uses an earlier data cut |
| Structure and terminology | Follows ICH E3 and sponsor templates, consistent terms | Regulatory writer | Missing required section or mixed terminology |
| Balance and tone | Neutral, non-promotional scientific language | Regulatory or medical reviewer | Promotional phrasing in results or discussion |
Report results by severity. A wrong primary endpoint value matters more than a hundred style fixes. Average scores hide the failures that matter.
How do you build a test set for CSR drafting?
Use studies where the answer is already known.
- Pick completed studies with final CSRs. Choose across phases, therapy areas and designs: a simple placebo-controlled trial, a multi-arm study, an adaptive design, a study with a messy safety profile.
- Feed the tool only what it would see in real use. Protocol, SAP, TLFs and templates. Hold back the final CSR as the reference.
- Seed known errors. Have a biostatistician plant inconsistencies in the inputs: a mislabeled population, a TLF that contradicts the SAP, a safety listing with a buried serious event. Measure how often the draft catches, repeats or hides them.
- Write a reference checklist per section. Medical writers and statisticians list what each section must state, must not state and must trace.
- Score with the right people. Statisticians on numbers and methods. Clinicians on interpretation. Safety physicians on narratives. Writers on structure and consistency.
- Retest on every change. A new model, template, prompt library or sponsor style means a new run on the same set.
Upstream quality matters too. If AI also helps produce the TLFs, test that step separately, as we covered in how to evaluate AI for statistical programming.
Checklist: what to ask an AI medical writing vendor
- Which source documents does the tool draft from, and can it cite the exact source for each sentence?
- What is the measured numeric error rate against TLFs on studies like ours?
- Who measured it, and were the reviewers statisticians and clinicians or internal staff?
- How does the tool handle conflicts between the protocol, SAP and TLFs: flag, resolve or ignore?
- How are safety narratives drafted and checked for completeness?
- What controls protect study data, such as role-based access and study-level data segregation?
- Is there an audit trail of what the AI wrote and what humans changed?
- What gets retested when the model, templates or prompts change?
- Can you run your tool on a test set we provide and report results by severity?
- Which reported time savings are your own measurements, and which are customer measurements?
ICON lists role-based access, study-level data segregation and audit-ready processes as baseline controls for regulated use. Ask for them in writing.
How Acumen helps
We give pharma teams the expert side of the evaluation. That means biostatisticians, clinicians, safety physicians and experienced regulatory writers who build test sets from completed studies, write section-level reference checklists, seed known errors and score AI drafts on a fixed rubric. You get item-level scores, failure examples ranked by severity and documentation you can bring to quality, regulatory and medical review.
See our medical affairs and regulatory AI data service for what a test set and scoring program include. For promotional content, see how to evaluate AI for MLR review.
FAQ
Can AI write a clinical study report?
AI can draft large parts of a clinical study report from the protocol, statistical analysis plan and tables, listings and figures. Published examples report big time savings, including Merck and McKinsey cutting first-draft time from 180 to 80 hours. Medical writers, statisticians and clinicians still need to review, correct and approve every section before submission.
How accurate are AI-generated CSR drafts?
It depends on the tool, the study and how accuracy is measured. McKinsey reports the Merck platform reduced errors by 50 percent. The published figures come from the companies involved, not independent studies. The only reliable answer for your studies is to test the tool on completed trials where you already hold the final, approved report.
What is the biggest risk of using AI for CSRs?
Fluent errors. A draft can read well and still misstate a value, describe an exploratory analysis as primary or understate a safety signal. ICON warns that small misunderstandings in data-heavy sections can spread into larger errors. That is why numeric checks, traceability and expert review of interpretation are the core of any evaluation.
Who should review AI-drafted clinical study reports?
Match the reviewer to the risk. Biostatisticians check numbers, populations and methods against the SAP and TLFs. Clinicians in the therapy area judge whether conclusions fit the evidence. Safety physicians review narratives and signals. Regulatory and medical writers check structure, consistency and tone. One reviewer type cannot cover all of these.
Do regulators allow AI in regulatory writing?
Regulators have set expectations rather than bans. The FDA and EMA Guiding Principles of Good AI Practice in Drug Development, released January 14, 2026, call for risk-based performance assessment, data governance, data quality and life cycle management. The sponsor remains responsible for the accuracy of what it submits, whoever or whatever drafted it.
How often should a CSR drafting tool be re-evaluated?
Re-evaluate on every material change: a new model version, new templates, new prompt libraries or a new therapy area. Between changes, sample real drafts on a set schedule, compare them with the final approved text and add new failure types to the test set. Keep the results as part of your quality documentation.